AU2007301966B2 - Novel antigens and antibodies associated to Pancreatic Ductal Adenocarcinoma - Google Patents

Novel antigens and antibodies associated to Pancreatic Ductal Adenocarcinoma Download PDF

Info

Publication number
AU2007301966B2
AU2007301966B2 AU2007301966A AU2007301966A AU2007301966B2 AU 2007301966 B2 AU2007301966 B2 AU 2007301966B2 AU 2007301966 A AU2007301966 A AU 2007301966A AU 2007301966 A AU2007301966 A AU 2007301966A AU 2007301966 B2 AU2007301966 B2 AU 2007301966B2
Authority
AU
Australia
Prior art keywords
pda
enolase
alpha
antibodies
enoa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007301966A
Other languages
English (en)
Other versions
AU2007301966A1 (en
Inventor
Paola Cappello
Francesco Novelli
Barbara Tomaino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Original Assignee
Ribovax Biotechnologies SA
Bioline Diagnostici SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies SA, Bioline Diagnostici SRL filed Critical Ribovax Biotechnologies SA
Publication of AU2007301966A1 publication Critical patent/AU2007301966A1/en
Application granted granted Critical
Publication of AU2007301966B2 publication Critical patent/AU2007301966B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007301966A 2006-09-29 2007-09-28 Novel antigens and antibodies associated to Pancreatic Ductal Adenocarcinoma Ceased AU2007301966B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06121552.1 2006-09-29
EP06121552 2006-09-29
EP06126726.6 2006-12-20
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (2)

Publication Number Publication Date
AU2007301966A1 AU2007301966A1 (en) 2008-04-03
AU2007301966B2 true AU2007301966B2 (en) 2013-02-21

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007301966A Ceased AU2007301966B2 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to Pancreatic Ductal Adenocarcinoma

Country Status (18)

Country Link
US (1) US8071721B2 (enExample)
EP (1) EP2069395B1 (enExample)
JP (1) JP2010505104A (enExample)
KR (1) KR20090094227A (enExample)
CN (1) CN101578295B (enExample)
AT (1) ATE542831T1 (enExample)
AU (1) AU2007301966B2 (enExample)
BR (1) BRPI0717282A2 (enExample)
CA (1) CA2664841A1 (enExample)
DK (1) DK2069395T3 (enExample)
EA (1) EA016731B1 (enExample)
ES (1) ES2381304T3 (enExample)
IL (2) IL197868A (enExample)
NO (1) NO20091662L (enExample)
NZ (1) NZ576409A (enExample)
PL (1) PL2069395T3 (enExample)
PT (1) PT2069395E (enExample)
WO (1) WO2008037792A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500964A (ja) * 2008-05-09 2012-01-12 デューク ユニバーシティ 癌の検出と治療における自己抗体
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
RU2656153C1 (ru) * 2013-12-20 2018-05-31 Девелопмент Сентер Фор Байотекнолоджи Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
MX2016009102A (es) 2014-01-13 2016-09-09 Berg Llc Composiciones de enolasa 1 (eno1) y sus usos.
CN115786317A (zh) * 2022-12-12 2023-03-14 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Marcus, et al., Electrophoresis. 2000, vol. 21, pages 2622-2636. *
Rush, et al. Nature BioTech. 2005, vol. 23, pages 94-101. *
Shen, J., et al., Cancer Research. 2004, vol. 64, pages 9018-9026. *
Stasyk, T. et al., Molecular Biology of the Cell, 2005, vol. 16, pages 4765-4780. *

Also Published As

Publication number Publication date
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
IL197868A0 (en) 2011-08-01
IL197868A (en) 2013-03-24
CA2664841A1 (en) 2008-04-03
EA200970332A1 (ru) 2009-10-30
DK2069395T3 (da) 2012-05-14
EP2069395A1 (en) 2009-06-17
EP2069395B1 (en) 2012-01-25
PT2069395E (pt) 2012-04-27
NO20091662L (no) 2009-06-29
ES2381304T3 (es) 2012-05-25
IL218442A0 (en) 2012-04-30
KR20090094227A (ko) 2009-09-04
ATE542831T1 (de) 2012-02-15
JP2010505104A (ja) 2010-02-18
CN101578295B (zh) 2013-02-27
BRPI0717282A2 (pt) 2013-10-15
US20100028907A1 (en) 2010-02-04
EA016731B1 (ru) 2012-07-30
US8071721B2 (en) 2011-12-06
CN101578295A (zh) 2009-11-11
AU2007301966A1 (en) 2008-04-03
NZ576409A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
AU2007301966B2 (en) Novel antigens and antibodies associated to Pancreatic Ductal Adenocarcinoma
Wang et al. An autoantigen atlas from human lung HFL1 cells offers clues to neurological and diverse autoimmune manifestations of COVID-19
Martelli et al. Integrated proteomic platforms for the comparative characterization of medulloblastoma and pilocytic astrocytoma pediatric brain tumors: a preliminary study
KR20170007671A (ko) 엑소좀 단백질 eif3a 특이반응 오토항체검출용 항원 조성물 및 이를 이용한 간암진단법
Zhang et al. Generation and characterization of an anti-GP73 monoclonal antibody for immunoblotting and sandwich ELISA
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
WO2010071788A1 (en) Pancreatic cancer markers and uses thereof
CA2909474C (en) New method for monitoring cancer and/or inflammatory reaction based on relb phosphorylation
Thakar et al. SUMOylation of the hepatoma‐derived growth factor negatively influences its binding to chromatin
KR20150129932A (ko) 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
Zurawel et al. Proteomic profiling of the mesenteric lymph after hemorrhagic shock: differential gel electrophoresis and mass spectrometry analysis
Ye et al. Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics
DK2447719T3 (en) proteins
EP4526341A1 (en) High affinity antibodies specifically binding to alpha-1,6-core-fucosylated alpha-fetoprotein
KR20120094711A (ko) 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
Cho et al. Glypican 3 binds to GLUT1 and decreases glucose transport activity in hepatocellular carcinoma cells
Miranda et al. Heterologous expression of Homo sapiens alpha-folate receptors in E. coli by fusion with a trigger factor for enhanced solubilization
ITTO20090697A1 (it) Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
EP3346271A1 (en) Methods and kits for detecting cancer
Tian et al. USP13 Regulates the Breast Tumor Proliferation and Migration through the Stabilization of PDCD4 Protein
Ferreira et al. Trimmed N-glycans define aggressive gastric cancer and predict clinical outcomes
Semaan Proteomics of putative protein biomarkers in human breast cancer tissues
G Gamage Biochemical And Structural Characterization Of The Core Subunits Of Gpi Transamidase
WO2011140478A2 (en) Compositions and methods for detecting acetylated sumo proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired